What is Bristol-Myers Squibb's D&A?

Bristol-Myers Squibb (BMY) reported D&A of $594M in Q1 2026.

How has Bristol-Myers Squibb's D&A changed year-over-year?

Bristol-Myers Squibb's D&A decreased by 41.3% year-over-year, from $1.01B to $594M.

What is the long-term trend for Bristol-Myers Squibb's D&A?

Over 4 years (2021 to 2025), Bristol-Myers Squibb's D&A has grown at a -21.7% compound annual growth rate (CAGR), from $10.69B to $4.01B.

Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.

Bristol-Myers Squibb BMY D&A

D&A at other companies

PfizerPFE

$1.61B-0.3%

Johnson & JohnsonJNJ

$2B+13.1%

IncyteINCY

$23.8M+6.4%

Oruka Therapeutics, Inc.ORKA

$43K+169%

Neurocrine BiosciencesNBIX

$7.2M+9.1%

CytokineticsCYTK

$3.38M+46.9%

Other financials

Income statement

See full

Revenue$11.5B+2.6%

Gross profit$8.1B-1.2%

Net income$2.7B+9.0%

EPS (diluted)$1.31+9.2%

Balance sheet

See full

Cash & equivalents$9.6B-12.0%

Total debt$44.7B-10.5%

Total equity$20.1B+15.4%

Total assets$86.5B-6.4%

Cash flow

See full

Operating cash flow$1.1B-43.5%

CapEx$347.0M+33.5%

Free cash flow$757.0M-55.3%

Valuation

See full

Market cap$117.46B+22.7%

Enterprise value$152.54B+15.1%

P/E16.2×-3.1×

P/S2.4×+0.4×

Profitability

See full

Gross margin70.5%0.0pp

Net margin15%+3.8pp

FCF margin24.6%-2.9pp

Returns & leverage

See full

Return on equity38.8%+7.3pp

Debt / equity2.2×-0.6×

Current ratio1.4×+0.1×

Where this comes from

Reported directly by Bristol-Myers Squibb in its filing.

Tagged under the XBRL concept us-gaap:DepreciationDepletionAndAmortization.

The official record: Bristol-Myers Squibb’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Bristol-Myers Squibb's d&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Bristol-Myers Squibb's D&A?: Bristol-Myers Squibb (BMY) reported D&A of $594M in Q1 2026.
How has Bristol-Myers Squibb's D&A changed year-over-year?: Bristol-Myers Squibb's D&A decreased by 41.3% year-over-year, from $1.01B to $594M.
What is the long-term trend for Bristol-Myers Squibb's D&A?: Over 4 years (2021 to 2025), Bristol-Myers Squibb's D&A has grown at a -21.7% compound annual growth rate (CAGR), from $10.69B to $4.01B.
What does D&A mean?: Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.